Sales for Sanofi's major blockbuster drug Dupixent are mainly fueled by its use as a treatment for atopical dermatitis, but the drug's other approved indications are also gaining ground.
All in all, Sanofi has cashed in EUR 1.047bn (USD 1.3bn) from selling Dupixent in Q1, amounting to a 45 percent incease.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.